Compare ADTN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTN | GERN |
|---|---|---|
| Founded | 1985 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 708.5M | 753.3M |
| IPO Year | 1994 | 1996 |
| Metric | ADTN | GERN |
|---|---|---|
| Price | $8.85 | $1.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $13.50 | $3.00 |
| AVG Volume (30 Days) | 1.2M | ★ 7.0M |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,035,099,000.00 | $183,403,000.00 |
| Revenue This Year | $18.56 | $147.42 |
| Revenue Next Year | $8.41 | $39.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.33 | ★ 522.13 |
| 52 Week Low | $6.93 | $1.04 |
| 52 Week High | $12.44 | $3.68 |
| Indicator | ADTN | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 53.91 |
| Support Level | $8.71 | $1.30 |
| Resistance Level | $9.15 | $1.37 |
| Average True Range (ATR) | 0.31 | 0.08 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 69.41 | 52.08 |
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support Segment which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.